期刊文献+

两种国产尼莫地平片在人体内的药动学和生物利用度 被引量:2

Pharmacokinetics Mechanism and Biology Utilization Rate of Two Kinds of Nimodipine in Human Body
下载PDF
导出
摘要 目的 :研究两种国产尼莫地平片在人体内的药动学 ,评价其相对生物利用度和生物等效性 ,为合理用药提供依据。方法 :将 2 0名健康志愿者随机分成两组 ,交叉单剂量口服尼莫地平片A和片B各 1 2 0mg ,采用HPLC法测定血清中尼莫地平的浓度。结果 :口服尼莫地平片后 ,尼莫地平片A和片B的主要药代动力学参数分别为Cmax(96 .4 8± 2 4 .31 )ng/ml、(1 0 3.35± 2 7.5 6 )ng/ml;Tmax分别为 (0 .5 6± 0 .0 5 )h、(0 .6 4± 0 .0 7)h ;T1 / 2 分别为 (1 .80± 0 .1 7)h、(1 .6 3± 0 .1 4 )h ;AUC0 -t分别为 (1 89.5± 2 0 .7)ng .h/ml、(1 75 .6± 2 3.5 )ng .h ./ml。结论 :尼莫地平片A相对于片B的人体生物利用度为(1 0 5 .6± 8.1 ) % 。 Objective: To study on the Pharmacokinetics mechanism of two kinds of Nimodipine in human body, evaluate the biological utilization rate and biological equivalent degree, and provide basis for prescribing drugs reasonably. Methods: Divide 20 cases of health postulant into two groups by random, alternately taking type A and type B of Nimodipine 120mg single dosage orally, determine of Nimodipine in blood by HPLC. Results: The main Pharmacokinetics parameters of A and B kinds of Nimodipine are respectively(96.48±24.31)ng/ml,(103.35±27.56)ng/ml in Cmax;(0.56±0.05)h,(0.64±0.07)h in Tmax;(1.80±0.17)h,( 1.63±0.14)h inT1/( 189.5±20.7)ng.h/ml,(175.6±23.5)ng.h./ml in AUC 0-t . Conclusion: The biological utilization rate of type A relative to type B is (105.6±8.1)%.These two kinds of Nimodipine are biological equivalent. \[
出处 《湖南中医药导报》 2003年第8期49-50,共2页 Hunan Guiding Journal of Traditional Chinese Medicine and Pharmacology
关键词 尼莫地平 高效液相色谱法 药代动力学 生物利用度 Nimodipine High Performance Liquid Chromatograpy (HPLC) Pharmacokinetics Biological utilization rate
  • 相关文献

参考文献2

共引文献18

同被引文献13

  • 1王正容,张奇志,蒋新国,苏丽娜.HPLC法测定大鼠血、脑组织和脑脊液中尼莫地平的浓度[J].中国临床药学杂志,2004,13(4):214-217. 被引量:7
  • 2张莉,李昕.RP-HPLC法测定血浆中尼莫地平浓度[J].中国药师,2004,7(11):865-867. 被引量:5
  • 3曹师磊,黄平,蔡佳,申云帆,陈钧,蒋新国.二种尼莫地平注射剂犬的药动学比较[J].中国医院药学杂志,2006,26(10):1212-1215. 被引量:3
  • 4Langley MS, Sorkin EM. Nimodipine-A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in cerebrovascular disease [J]. Drugs, 1989, 37 (5) : 669-699.
  • 5Tomassoni D, Lanari A, Silvestrelli G, et al. Nimodipine and its use in cerebrovascular disease: evidence from recent preclinical and controlled clinical studies [J]. Clin Exp Hypertens, 2008, 30 (8) : 744-766.
  • 6Langley MS, Sorkin EM. Nimodipine: A review of its phammacodynamic and pharmacokinetic Properties and therapeutic potential in cerebrovascular disease [J]. Drugs, 1989,37:669.
  • 7Patel VB, Misra AN, Marfatia YS. Preparation and comparative clinical evaluation of liposomal gel of benzoyl peroxide for acne [J]. Drug Der InudPharm, 2001,27(8) :863.
  • 8Keon-Hyoung Song, Suk-Jae Chuang, Chang-Koo Shim. Preparation and evaluation of proliposomes containing salmon calcitonin [J]. J Controlled Release, 2002,84:27.
  • 9Dredand I, et al. Evaluation of mathemaical model describing drug release from lipophilic matrices[J]. Int J Pharm, 1996,145:61.
  • 10吴芳.脂质体制剂的研究及应用[J].中国医药工业杂志,1999,30(12):564-568. 被引量:16

引证文献2

二级引证文献15

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部